Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Ki-67 labeling index in glioblastoma; does it really matter?

Alkhaibary A, Alassiri AH, AlSufiani F, Alharbi MA.

Hematol Oncol Stem Cell Ther. 2018 Dec 8. pii: S1658-3876(18)30115-8. doi: 10.1016/j.hemonc.2018.11.001. [Epub ahead of print]

2.

Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma.

Wong E, Nahar N, Hau E, Varikatt W, Gebski V, Ng T, Jayamohan J, Sundaresan P.

Asia Pac J Clin Oncol. 2019 Feb;15(1):5-9. doi: 10.1111/ajco.12826. Epub 2018 Jan 16.

PMID:
29336530
3.

Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.

Tsidulko AY, Kazanskaya GM, Kostromskaya DV, Aidagulova SV, Kiselev RS, Volkov AM, Kobozev VV, Gaitan AS, Krivoshapkin AL, Grigorieva EV.

Tumour Biol. 2017 Sep;39(9):1010428317724282. doi: 10.1177/1010428317724282.

PMID:
28945172
4.

Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.

Pollack IF, Hamilton RL, Burnham J, Holmes EJ, Finkelstein SD, Sposto R, Yates AJ, Boyett JM, Finlay JL.

Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5.

PMID:
12015841
5.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
6.

Outcome of patients with glioblastoma in Saudi Arabia: Single center experience.

Altwairgi AK, Algareeb W, Yahya G, Maklad AM, Aly MM, Al Shakweer W, Balbaid A, Alsaeed E, Alhussain H, Orz Y, Lary A, Elyamany A.

Mol Clin Oncol. 2016 May;4(5):756-762. Epub 2016 Mar 10.

7.

Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder.

Vetterlein MW, Roschinski J, Gild P, Marks P, Soave A, Doh O, Isbarn H, Höppner W, Wagner W, Shariat SF, Brausi M, Büscheck F, Sauter G, Fisch M, Rink M.

Transl Androl Urol. 2017 Dec;6(6):1018-1026. doi: 10.21037/tau.2017.11.10.

8.

Relationship between Ki-67 labeling index and survival in high-grade glioma patients treated after surgery with tamoxifen.

Mastronardi L, Guiducci A, Puzzilli F, Ruggeri A.

J Neurosurg Sci. 1999 Dec;43(4):263-70.

PMID:
10864388
9.

Intraoperative serum lactate is not a predictor of survival after glioblastoma surgery.

Cata JP, Bhavsar S, Hagan KB, Arunkumar R, Grasu R, Dang A, Carlson R, Arnold B, Popat K, Rao G, Potylchansky Y, Lipski I, Ratty S, Nguyen AT, McHugh T, Feng L, Rahlfs TF.

J Clin Neurosci. 2017 Sep;43:224-228. doi: 10.1016/j.jocn.2017.05.004. Epub 2017 Jun 7.

PMID:
28601568
10.

Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors.

Belev B, Brčić I, Prejac J, Golubić ZA, Vrbanec D, Božikov J, Alerić I, Boban M, Razumović JJ.

World J Gastroenterol. 2013 Jan 28;19(4):523-7. doi: 10.3748/wjg.v19.i4.523.

11.

Nuclear markers (star volume, mitotic index, AgNOR and Ki-67) of the primary tumor and its metastasis in non-small cell lung carcinomas.

Matheus RS, Bernardi Fdel C, Gallo CP, da Silva AP, Rodrigues OR, Capelozzi M, Lopes A, Fenezelian S, Saldiva PH, Capelozzi VL.

Pathol Res Pract. 2004;200(1):13-23.

PMID:
15157046
12.

Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.

Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, Hirakawa K.

Cancer. 1996 Jan 15;77(2):373-80.

PMID:
8625247
13.

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.

Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G, Tőkés T, Molnár BÁ, Molnár IA, Vári-Kakas S, Kulka J, Tőkés AM.

Diagn Pathol. 2017 Feb 21;12(1):20. doi: 10.1186/s13000-017-0608-5.

14.

Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.

Wang X, Chen Y, Zhang S, Zhang L, Liu X, Zhang L, Li X, Chen D.

J Neurooncol. 2015 Nov;125(2):277-85. doi: 10.1007/s11060-015-1919-6. Epub 2015 Sep 3.

PMID:
26334317
15.
16.

Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.

Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, Delfini R.

Tumori. 2007 May-Jun;93(3):248-56.

PMID:
17679459
17.

High expression of DNA topoisomerase IIalpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients.

Bredel M, Piribauer M, Marosi C, Birner P, Gatterbauer B, Fischer I, Ströbel T, Rössler K, Budka H, Hainfellner JA.

Eur J Cancer. 2002 Jul;38(10):1343-7.

PMID:
12091064
18.

New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer.

Hao S, He ZX, Yu KD, Yang WT, Shao ZM.

Oncotarget. 2016 Apr 26;7(17):24824-31. doi: 10.18632/oncotarget.8531.

19.

Expression of phosphatase and tensin homolog, epidermal growth factor receptor, and Ki-67 in astrocytoma: A prospective study in a tertiary care hospital.

Saha R, Chatterjee U, Mandal S, Saha K, Chatterjee S, Ghosh SN.

Indian J Med Paediatr Oncol. 2014 Apr;35(2):149-55. doi: 10.4103/0971-5851.138983.

20.

Significance of conventional and new prognostic factors for locally confined renal cell carcinoma.

Hofmockel G, Tsatalpas P, Müller H, Dämmrich J, Poot M, Maurer-Schultze B, Müller-Hermelink HK, Frohmüller HG, Bassukas ID.

Cancer. 1995 Jul 15;76(2):296-306.

PMID:
8625106

Supplemental Content

Support Center